Type II Diabetes Drug Fails Primary Endpoint

Tuesday, July 24, 2007

Metabasis and Daiichi Sankyo issued negative results from a phase IIb trial of CS-917 for the treatment of type II diabetes. This multi-center, double-blind, placebo-controlled trial enrolled 392 subjects who were divided into four treatment arms to receive CS-917 at 50 mg BID or 100 mg BID, metformin at 850 mg BID or placebo, for three months. 

[Read More]

Fraudulent Study Broker Cherie Thibodeau Continues to Bilk Sites

Friday, July 20, 2007

As a public service to sites, CROs and biopharmaceutical companies, CenterWatch is posting a long excerpt of this week’s CWWeekly article about fraudulent study broker, Cherie Thibodeau.

If you have been defrauded of funds by Cherie Thibodeau, please contact CenterWatch at editorial@centerwatch.com.

[Read More]

Recent Industry Personnel News

Wednesday, July 18, 2007

  • London-based CRO Premier Research Group hired David Fitts, MPH, Ph.D as executive director, biostatistics. Fitts comes to Premier from EMD Pharmaceutical, part of German-based Merck KGaA, where he was vice president of the clinical R&D unit’s global biostatistics and data services group. Fitts will now be responsible for all of Premier biostatistics operations in the U.S.

[Read More]

Encorium Group Scores $1.7 million Phase II Contract

Monday, July 16, 2007

Wayne, Pa.-based CRO Encorium Group has inked a $1.7 million deal to manage a phase II trial in major depressive disorder for an unnamed biotech company based in Japan. Encorium will provide site management and monitoring, data management, biostatistical support and medical writing for the study. Encorium stated it intends to pursue further opportunities in the Japanese market and has made that market one of its key long-term business strategies. Recently, the company signed a $3.8 million contract to conduct phase IIb clinical trials with a new antiviral agent for the treatment of shingles (herpes zoster).

[Read More]